Patients who are receiving conventional therapy according to the MOH protocol.

Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy

COVID-19

LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.
Dose:
One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour

Licorice extract

Faculty of Medicine, Assiut University

Complementary Intervention for COVID-19

Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine

Conversion of RT-PCR indicates positive for novel coronavirus RNA to negative

Decrease number of patients that require respiratory support , management in the Intensive Care Unit (ICU) and need Mechanical Ventilation Support with endotracheal intubation.

A pilot study for evaluation of the potential therapeutic effect of food supplement, licorice extract, and Boswellia Serrata gum

Adel Gomaa

Professor of medical pharmacology

Egyptian Biomedical Research Network

25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)

25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2

Renal Stones

AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma

AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)

Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)

Potassium Sodium Hydrogen Citrate

Mohamed Salim Ahmed Al-Marhoon

Treatment of Renal Stones With Frankincense (Luban)

Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial

The participants intolerance of the treatment or development of side effects that are not known complications of the presence of stones or new adverse reactions

Senior Consultant Urological Surgeon and Head of Urology

Sultan Qaboos University

Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.

Breast Cancer

Boswellia is an extract from frankinscense

Boswellia

Medical University of South Carolina

A "Window Trial" on Boswellia for Breast Cancer Primary Tumors

A "Window Trial" on Boswellia, an Extract From Frankincense, for Breast Primary Tumors

Change in tumor proliferation rate will be based on Ki67, CD31 and TUNEL assays in biopsies pre and post treatment with boswellia

Safety data will be tabulated by type and grade of adverse event and will use CTCAE v. 4.0

Additional changes in tumors as a result of boswellia intake will be analyzed through immunohistochemistry on paraffin-embedded tumors.

Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.

Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.

Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
cyanocobalamin : 50 ug/day given orally
Boswellia serrata extract : 4x (3-12.5) ml/day given orally, that is 720-3000mg of total Boswellic acids (three isomers)/day

Arm I (Intervention)

Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
cyanocobalamin : 50 ug/daygiven orally

Arm II (Control)

Total

Age, Customized

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Baseline measure was acquired for 11 patients. Six on Arm I and five on Arm II.

Baseline edema measure

The relative change from baseline will be assessed longitudinally, however, the main comparison of interest is the relative change at the 4-month evaluation. For each patient change = edema at follow up - baseline edema

Change From Pooled Baseline in Peritumoral Brain Edema

The relative change from baseline will be assessed longitudinally, however, the main comparison of interest is the relative change at the 4-month evaluation.For each patient change = edema at follow up - baseline edema.

Change From Baseline in Peritumoral Brain Edema

The relative change from baseline will be assessed longitudinally, however, the main comparison of interest is the relative change at the 4-month evaluation. For each patient change = edema at follow up - baseline edema.

Quality of life as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items (EORTC QLQ-C30)

Quality of Life at 6 Months

Percentage of participants with tumor progression (>25% increase in tumor volume compared to time 0) will be measured from enrollment to documented progression or death whichever comes first. The method used to calculate the time to tumor progression was Kaplan Meier test method to define the 95% confidence levels.

Time-to-tumor-progression: Percentage of Patients With Tumor Progression at 6 Months

Time-to-tumor-progression: Percentage of Patients With Tumor Progression at 1 Year

Overall survival will be measured from the date of enrollment to date of death or last contact. Survival will be evaluated by the Kaplan Meier method to evaluate the median survival and 1 year survival rates.

Overall Survival: Percentage of Patients That Were Alive at 1 Year

The 3-day food diary will be used to assess the dietary intake and to increase eating awareness of patients.

Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
cyanocobalamin : 50 ug/day given orally

Food Intake as Assessed by the Block 98 Food Frequency Questionnaire and a 3-day Food Record

Overall Study

Dr. Glen Stevens

Brain and Central Nervous System Tumors

Cerebral Edema

Boswellia serrata extract

cyanocobalamin

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme

Phase II Randomized Evaluation of 5-Lipoxygenase Inhibition by Herbal Complementary and Alternative Medicine Approach Compared to Control as an Adjuvant Therapy in Newly Diagnosed and Recurrent High-grade Gliomas

boswellia occulta/syöpä

Complementary Intervention for COVID-19

Treatment of Renal Stones With Frankincense (Luban)

A "Window Trial" on Boswellia for Breast Cancer Primary Tumors

Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme

Täydellisin lääketieteellinen tietokanta tieteen tukemana